Conference Call with Indegene Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Services company Indegene announced Q3FY25 results Achieved revenue of Rs 7,204 million in Q3FY25 compared to Rs 6,734 million during Q3FY24, a growth of 4.9% QoQ. Achieved PAT of Rs 1,097 million compared to Rs 988 million during Q3FY24, a growth of 19.6% QoQ. PAT margin: 15.2% for Q3FY25. EBITDA: Rs 1,501 million compared to Rs 1,499 million during Q3FY24. EBITDA margin: 20.8% for Q3FY25. Manish Gupta, Chairman and CEO, Indegene, said: “We have consistently grown our revenue, maintaining stable and profitable growth, and our Q3FY25 numbers reflect this. We achieved revenue growth of 4.9% QoQ driven by continued traction with large pharma customers and growth momentum with mid-size pharma customers. Our largest customer is continuing to grow, and we are doing a run-rate of a tad below USD 50 million with this customer” “We are seeing a steady increase in the revenues from our Top 5 customers, which have grown 3.1% sequentially in this period.” Suhas Prabhu, CFO, Indegene, said: ““Q3FY25 was another successful quarter for Indegene. We improved our EBITDA margin from 18.4% in Q2FY25 to 20.8% in Q3FY25. This was achieved via ongoing productivity improvement through better capacity management and automation, which helped absorb the impact of the annual employee wage hike effective July, fully and beyond” “Our earnings growth continues with PAT margin also increasing to 15.2% for the quarter, in line with our EBITDA performance. PAT has grown from INR 917 million in Q2FY25 to Rs 1,097 million in Q3FY25, a growth of 19.6% sequentially.” Result PDF